On November 7, 2022 Imago BioSciences, Inc. ("Imago") (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, reported that Hugh Young Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in two upcoming investor conferences (Press release, Imago BioSciences, NOV 7, 2022, View Source [SID1234623246]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

H.C. Wainwright 3rd Annual Precision Oncology Conference. Dr. Rienhoff will present on Monday, November 14 at 12:30 pm ET.

Stifel Healthcare Conference. Dr. Rienhoff will present on Wednesday, November 16th at 8:00 am ET.

Interested parties can access the live webcasts for these conferences from the Investor Relations section of the company’s website at www.imagobio.com. The webcast replays will be available after the conclusion of each conference for approximately 90 days.